Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for early chemotherapy-induced cardiotoxicity
2009-016930-29Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ranolazine in chemotherapy-induced cardiotoxicity (CIC) (3 arms), sponsored by Menarini Group. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Jan 2010; status: completed.
02
Drugs
ranolazine
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)
Beyond the preview
Go deeper on 2009-016930-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016930-29.